REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

NCT05902533 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Anal Cancer

Interventions

RADIATION: Radiation (reduced elective nodal dose (30.6 Gy)
DRUG: Capecitabine
DRUG: Mitomycin c

Sponsor

University of Cincinnati